Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kuros BiosciencesCSBTF 72 EV-to-OCF is -1,912.96 as of Jul. 19, 2026. GuruFocus rates CSBTF with a GF Score™ of 72/100 and a GF Value™ of $51.28 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 99.77% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Kuros Biosciences's Enterprise Value is $989.0 Mil.
Kuros Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.5 Mil. Therefore, Kuros Biosciences's EV-to-OCF for today is -1,912.96.
The historical rank and industry rank for Kuros Biosciences's EV-to-OCF or its related term are showing as below:
CSBTF'
s EV-to-OCF Range Over the Past 10 Years
Min: -2526.34 Med: -3.74 Max: 345.53
Current: -1759
During the past 13 years, the highest EV-to-OCF of Kuros Biosciences was 345.53. The lowest was -2526.34. And the median was -3.74.
CSBTF's EV-to-OCF is ranked better than 99.77% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.76
vs CSBTF: -1759.00
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kuros Biosciences (OTCPK:CSBTF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kuros Biosciences's PE Ratio (TTM) for today is calculated as:
Kuros Biosciences's share price for today is $25.5696.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.089.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kuros Biosciences EV-to-OCF Related Terms
Kuros Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's EV-to-OCF falls into.
Kuros Biosciences's current Enterprise Value is $989.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a EV-to-OCF of -1,912.96 as of Jul. 19, 2026. According to the industry distribution chart, Kuros Biosciences ranks #2 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 0.2%.
Is Kuros Biosciences' EV-to-OCF too high?
Kuros Biosciences' current EV-to-OCF is -1,912.96. Based on the distribution chart, Kuros Biosciences ranks #2 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kuros Biosciences has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #2 out of 853 companies for EV-to-OCF. This places Kuros Biosciences in the top 0% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.76, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current EV-to-OCF is -1,912.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $51.28, compared to a current price of $25.57 — trading 50.1% below its estimated fair value. The current EV-to-OCF is -1,912.96. Kuros Biosciences' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current EV-to-OCF is -1,912.96 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $25.57 is trading 50.1% below its estimated GF Value™ of $51.28.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
EV-to-OCF: -1,912.96
GF Value™: $51.28 vs. price of $25.57 (50.1% below fair value)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
72GF Score
Get the complete analysis for CSBTF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
